Akeso Biomedical is developing targeted antimicrobial therapies to combat bacterial infections that are resistant to existing treatments. The company focuses on creating novel compounds that enhance efficacy and reduce treatment duration, addressing the growing global health threat of antibiotic resistance.
Funding
$573.9K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The rise of antibiotic-resistant bacteria poses a significant threat to global health, rendering many existing treatments ineffective. Current antimicrobial therapies often require prolonged treatment durations and fail to adequately address the underlying mechanisms of resistance, leading to increased morbidity and mortality.
Solution
Akeso Biomedical is developing targeted antimicrobial therapies designed to combat bacterial infections resistant to conventional treatments. The company's approach focuses on creating novel compounds that enhance treatment efficacy while simultaneously reducing the duration of therapy. By targeting specific bacterial mechanisms and resistance pathways, Akeso Biomedical aims to overcome the limitations of existing antibiotics and provide more effective solutions for patients with drug-resistant infections. These therapies are designed to minimize off-target effects and improve patient outcomes in the face of increasing antibiotic resistance.
Target Audience
The primary target audience includes hospitals, healthcare providers, and patients suffering from bacterial infections resistant to conventional antibiotic treatments.
Features
- Novel antimicrobial compounds targeting specific bacterial resistance mechanisms
- Enhanced efficacy against multi-drug resistant bacterial strains
- Reduced treatment duration compared to existing therapies